Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.
GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."
Pfizer will sell two Novartis drugs in the UK.
Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.
The FDA has approved Arnuity Ellipta for asthma.
The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
It could also eat into Merck's Pneumovax sales.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
US sales fell 10%, and corruption allegations in China ate into emerging-market sales.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled